致：香港交易及結算所有限公司 公司名稱: 梅斯健康控股有限公司（於開曼群島註冊成立的有限公司） 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 FF301 呈交日期: 2025年12月3日 本月底法定/註冊股本總額： USD 1,500,000 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02415 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 607,170,950 | | | | 607,170,950 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 梅斯健康控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02415 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | USD | | 0.0001 | USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 15,000,000,000 | USD | | 0.0001 | US ...

Core Viewpoint - The stark valuation difference between Nongfu Spring and China Resources Beverage, despite similar product pricing, highlights the underlying value dynamics in the bottled water industry, with Nongfu Spring commanding a market capitalization of 599.4 billion HKD compared to China Resources Beverage's 26.4 billion HKD [2][7]. Group 1: Market Performance - As of October 17, 2023, Nongfu Spring's market capitalization increased by 217.6 billion HKD, while China Resources Beverage's decreased by 1.7 billion HKD, illustrating a significant valuation gap where one Nongfu Spring is equivalent to approximately 23 China Resources Beverages [7]. - In the first half of 2025, Nongfu Spring reported revenue of 25.622 billion CNY and a net profit of 7.622 billion CNY, with bottled water revenue accounting for 36.9% of total revenue. In contrast, China Resources Beverage had revenue of 6.206 billion CNY and a net profit of only 0.805 billion CNY, with bottled water revenue making up 84.6% of its total [7][9]. Group 2: Profitability Metrics - Nongfu Spring's gross margin reached 60.3% in the first half of 2025, while China Resources Beverage's was 46.7%, indicating a 13.6 percentage point advantage for Nongfu Spring [9][19]. - The gross margins for Nongfu Spring have consistently been higher than those of China Resources Beverage, with a notable difference of 10.8 percentage points in 2024 [9]. Group 3: Competitive Landscape - The bottled water market has seen intense competition, with Nongfu Spring emerging as a leader, while China Resources Beverage has struggled to maintain its market position, leading to a decline in market share for the latter [9][10]. - Nongfu Spring has diversified its product offerings beyond bottled water, with tea beverages contributing significantly to its revenue, while China Resources Beverage is still in the process of expanding its beverage portfolio [9][10]. Group 4: Supply Chain and Production Models - Nongfu Spring operates a fully self-sufficient production model, controlling its supply chain from water source to bottling, which enhances its cost efficiency and profitability [19][22]. - In contrast, China Resources Beverage relies heavily on a contract manufacturing model, which incurs additional costs and risks associated with outsourcing production [19][22][27]. Group 5: Future Strategies - China Resources Beverage is actively working to increase its self-production capacity, aiming for 60% of its bottled water production to come from its own facilities by 2025, as part of its strategic expansion plan [28][29]. - The industry is witnessing a trend towards self-built production facilities, as companies recognize the importance of supply chain control in maintaining competitive advantage [30][31].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 梅斯健康控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02415 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | USD | | 0.0001 | USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 15,000,000,000 | USD | | 0.0001 | USD | | 1 ...

Financial Performance - For the first half of 2025, MedSci Healthcare Holdings Limited achieved total revenue of RMB 125.2 million, representing a year-on-year growth of 13.2%[12] - Gross profit for the same period was RMB 77.5 million, with a year-on-year increase of 14.1%[12] - Net profit surged to RMB 13.2 million, reflecting a remarkable year-on-year growth of 5,238.3%[12] - The company's revenue for the six months ended June 30, 2025, was approximately RMB 125.2 million, representing a 13.2% increase from RMB 110.7 million for the same period in 2024[27] - Gross profit for the same period was RMB 77.5 million, up 14.1% from RMB 67.9 million year-over-year[27] - The net profit attributable to shareholders was RMB 13.2 million, a significant increase of 5,238.3% compared to RMB 248,000 in the previous year[27] - The precision omnichannel marketing solutions generated revenue of RMB 56.1 million, a 34.1% increase from RMB 41.9 million in the prior year[30] - Revenue from real-world clinical research (RWS) solutions rose by 22.7% to RMB 16.6 million, up from RMB 13.6 million year-over-year[32] - For the six months ended June 30, 2025, the company reported a pre-tax profit of RMB 14,521,000 compared to a loss of RMB 240,000 in the same period of 2024, indicating a significant turnaround in performance[126] Membership and Client Base - The company registered over 5.6 million cumulative members and 3.33 million certified doctors by June 30, 2025[11] - The number of active clients reached 613, including 525 core pharmaceutical, biotechnology, and medical device companies, with a 100% revenue retention rate from the top 10 clients[18] - As of June 30, 2025, the online professional physician platform has approximately 3.3 million registered physician users, with an average of about 3.0 million active users during the reporting period[14] AI and Technology Development - MedSci launched three AI products: iMED_AI, NovaX, and ElavaX, aimed at enhancing medical decision-making and operational efficiency[10] - AI-related business revenue reached RMB 5.6 million, contributing significantly to the company's growth trajectory[12] - The company is building a comprehensive AI empowerment system covering the entire pharmaceutical industry, aiming to release new growth momentum[12] - The company is focusing on AI-driven physician platform solutions to enhance information integration and push capabilities, reducing the reliance on manual services and improving efficiency[15] - The introduction of AI technologies is expected to drive significant growth in revenue from AI services, with the company already achieving some scale in AI service income[25] International Strategy and Market Expansion - The company is advancing its international strategy, focusing on expanding overseas markets and global service networks[12] - The company is transitioning to a "multi-agent collaboration" model to enhance business adaptability and innovation, with a focus on international market expansion, particularly in Southeast Asia[24] - The company plans to strengthen its international service model and technical capabilities to enhance supply chain resilience and establish a global pharmaceutical ecosystem[24] Operational Efficiency and Cost Management - Sales cost increased by approximately 11.8% from RMB 42.8 million for the six months ended June 30, 2024, to RMB 47.8 million for the same period in 2025[35] - Selling and distribution expenses decreased by approximately 10.8% from RMB 37.9 million for the six months ended June 30, 2024, to RMB 33.8 million for the same period in 2025[38] - Administrative expenses decreased by approximately 36.9% from RMB 35.8 million for the six months ended June 30, 2024, to RMB 22.6 million for the same period in 2025[39] - R&D expenses increased by approximately 63.8% from RMB 12.0 million for the six months ended June 30, 2024, to RMB 19.7 million for the same period in 2025, driven by increased investment in AI[40] Shareholder Information and Corporate Governance - As of June 30, 2025, Dr. Li holds a beneficial interest in 177,929,750 shares, representing 29.30% of the company, while Dr. Zhang holds 140,972,700 shares, representing 23.22%[74] - Major shareholders include Microhealth Limited with 29.30% and Dtx Health Limited with 23.22% of the company's shares as of June 30, 2025[78] - The company remains committed to maintaining high corporate governance standards and has complied with all applicable codes as of June 30, 2025[60] - The company adopted an equity incentive plan on April 20, 2022, aimed at attracting and retaining talent to drive long-term development[83] Dividend and Share Incentive Plans - The board has decided to distribute an interim dividend of HKD 0.011 per share for the six months ending June 30, 2025, compared to no dividend in the same period of 2024[116] - The total number of shares that can be granted under the share incentive plan is capped at 10% of the company's issued share capital as of the adoption date, which amounts to 60,717,095 shares[107] - The equity incentive plan allows participants to realize economic benefits through the sale of reward shares, capped at 20% of the relevant shares per year[89] Financial Position and Cash Flow - Cash and cash equivalents amounted to approximately RMB 315.6 million as of June 30, 2025, down from RMB 366.9 million as of December 31, 2024[49] - The company had no bank borrowings or other interest-bearing debts as of June 30, 2025, except for lease liabilities totaling approximately RMB 8.3 million[50] - The fair value financial assets of the group increased from approximately RMB 552.9 million as of December 31, 2024, to approximately RMB 670.8 million as of June 30, 2025, primarily due to an increase in invested financial products[51] - The company recorded a total comprehensive income of RMB 7,520,000 for the six months ended June 30, 2025, compared to RMB 6,045,000 in 2024[122] - Cash flow from operating activities for the six months ended June 30, 2025, was RMB 20,719,000, a substantial increase from RMB 5,988,000 in the prior year, reflecting improved operational efficiency[126] Risks and Liabilities - The company faces foreign exchange risks primarily from fluctuations between the Renminbi and other currencies, particularly the Hong Kong Dollar and US Dollar, which could impact financial performance[73] - The company has not entered into any currency hedging transactions for the six months ending June 30, 2025[73] - There were no significant contingent liabilities or pledged assets as of June 30, 2025[54][55]

Core Viewpoint - Meis Health (02415) announced that its subsidiary, Shanghai Meis Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for patients with acute and intercritical gout, with a project value of approximately RMB 21 million [1] Group 1 - The project aims to systematically evaluate the effectiveness and safety of IL-1β monoclonal antibody treatment through a combination of prospective and retrospective observational studies [1] - The company leverages over a decade of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies [1] - The digital solutions provided by the company aim to empower the healthcare ecosystem and improve the quality of medical services [1]

Core Viewpoint - Mees Health (02415.HK) announced that its subsidiary, Shanghai Mees Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for gout patients [1] Group 1 - The project aims to systematically evaluate the effectiveness and safety of IL-1β monoclonal antibody treatment for patients during both acute and intercritical phases of gout through a combination of prospective and retrospective observational studies [1] - The project is valued at approximately RMB 21 million [1] - The group leverages over a decade of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies, thereby providing digital solutions to enhance the healthcare ecosystem and improve medical quality [1]

Core Viewpoint - Mees Health (02415) announced that its subsidiary, Shanghai Mees Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for acute and intercritical gout patients [1] Group 1 - The project amount is approximately RMB 21 million [1] - The project aims to systematically evaluate the effectiveness and safety of the treatment through a combination of prospective and retrospective observational studies [1] Group 2 - The company leverages over ten years of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies [1] - The digital solutions provided by the company aim to empower the medical ecosystem and improve healthcare quality [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本集團依託於積累十餘年的互聯網醫生平台，應用大數據和人工智能技術鏈接醫 生、患者和藥械企業，提供數字化解決方案，賦能醫療生態，改善醫療質量。 承董事會命 梅斯健康控股有限公司 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 自願性公告 中標 中國某藥企「痛風智管計劃」大型真實世界研究項目 本公告由梅斯健康控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）自願 發佈，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，近期，本公司的子公司上海梅斯醫藥 科技有限公司中標中國某藥企的一項大型真實世界研究項目，該項目旨在「透過前 瞻性與回顧性相結合的觀察性研究，系統評估IL-1β單抗治療痛風急性期與間歇期 患者的有效性與安全性」，項目金額為約人民幣2, ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 梅斯健康控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02415 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | 本月 ...